Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas
NCT02762448 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2018-04-19
Summary
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study
Conditions
- Hepatitis c
Interventions
- DRUG
-
Daclatasvir+ Asunaprevir
HCV clearance and complete regression of NHL by ASV+ DCV
Sponsors & Collaborators
-
Tainan Municipal Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-31
- Primary Completion
- 2018-01-31
- Completion
- 2018-04-18
More Related Trials
-
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
NCT03004625 ·Status: COMPLETED ·Phase: PHASE3
-
Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C
NCT00629824 ·Status: COMPLETED ·Phase: PHASE4
-
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
NCT00630084 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
NCT02194998 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
NCT02496078 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
NCT01753557 ·Status: COMPLETED ·Phase: PHASE3
-
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
NCT02250001 ·Status: COMPLETED
-
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy
NCT01024894 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection
NCT02377856 ·Status: COMPLETED ·Phase: PHASE4
-
Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy
NCT02060058 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
NCT02340962 ·Status: COMPLETED ·Phase: PHASE2
-
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
NCT00543244 ·Status: UNKNOWN
-
Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
NCT00154869 ·Status: UNKNOWN ·Phase: PHASE3
-
Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin
NCT00456248 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
NCT01468584 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
NCT02580474 ·Status: COMPLETED ·Phase: PHASE4
-
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
NCT02107365 ·Status: COMPLETED ·Phase: PHASE2
-
Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C
NCT00980161 ·Status: UNKNOWN
-
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
NCT01290731 ·Status: COMPLETED ·Phase: PHASE3
-
Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C
NCT00148863 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects
NCT01459419 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers
NCT00255359 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
NCT01749150 ·Status: COMPLETED ·Phase: PHASE2
-
NIDDM and IR in Combination Therapy for CHC
NCT00687999 ·Status: COMPLETED ·Phase: NA
-
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
NCT04638439 ·Status: COMPLETED ·Phase: PHASE1